Acalabrutinib – Targeted Therapy

Acalabrutinib is a highly selective, second-generation Bruton's tyrosine kinase (BTK) inhibitor. It represents a significant advancement in the targeted therapy of B-cell malignancies, offering more precise action compared to its predecessors.

The mechanism of action involves forming a covalent bond with a cysteine residue in the active site of the BTK enzyme. Bruton's tyrosine kinase is a critical component of the B-cell receptor signaling pathway, which is essential for the survival, proliferation, and migration of malignant B-lymphocytes. By blocking this pathway, acalabrutinib halts tumor growth and induces cancer cell death. Due to its high selectivity, the drug minimizes off-target inhibition of other kinases, which reduces the risk of specific side effects such as atrial fibrillation and bleeding.

The medication is administered orally and allows for long-term disease control with a favorable safety profile.

Wikipedia page

Indications

Acalabrutinib is indicated for the treatment of adult patients with the following conditions:

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): as monotherapy or in combination with obinutuzumab for previously untreated patients, and as monotherapy for relapsed or refractory cases.
Mantle Cell Lymphoma (MCL): for patients who have received at least one prior therapy.

Dosage and administration

Acalabrutinib dosing is standardized but requires consideration of concomitant medications.

Standard Dose: 100 mg taken twice daily (approximately every 12 hours).
Administration: capsules or tablets should be swallowed whole, with or without food.
Drug Interactions: co-administration with proton pump inhibitors (PPIs) should be avoided as they decrease drug absorption. If antacids are required, they should be separated by at least 2 hours.
Missed Dose: if more than 3 hours have passed since the scheduled time, the dose should be skipped and the next one taken at the usual time.

The use of acalabrutinib is restricted in the following situations:

Hypersensitivity: allergic reactions to the active substance or any excipients.
Pregnancy and Lactation: potential risk to the fetus; breastfeeding is contraindicated during treatment and for 2 weeks after the final dose.
Pediatric Use: safety and efficacy in patients under 18 years of age have not been established.
Severe Hepatic Impairment: use is not recommended due to lack of clinical data.

Acalabrutinib therapy may be associated with the following adverse reactions:

General: headache (very common, typically resolving within the first month of treatment), fatigue.
Hematologic: anemia, neutropenia, and thrombocytopenia (regular blood monitoring is required).
Gastrointestinal: diarrhea, nausea, and abdominal pain.
Infections: increased risk of respiratory tract infections and opportunistic infections.
Cardiovascular: potential risk of atrial fibrillation and hypertension (lower incidence compared to first-generation inhibitors).
Bleeding: increased risk of hemorrhage, especially when co-administered with anticoagulants.

Frequently Asked Questions

Acalabrutinib is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor. BTK is a key protein that transmits signals for the survival and proliferation of malignant B-cells. By blocking this enzyme, acalabrutinib halts tumor growth and causes cancer cells to leave protective environments (like lymph nodes), making them more susceptible to cell death.

The primary indications for acalabrutinib are chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. It is often preferred due to its greater selectivity compared to first-generation BTK inhibitors.

Acalabrutinib requires an acidic environment in the stomach for proper absorption. Acid-reducing medications, such as omeprazole or pantoprazole, significantly decrease acalabrutinib levels in the blood, which can render the treatment ineffective. If antacids are necessary, they should be taken at least 2 hours before or 2 hours after acalabrutinib.

Although acalabrutinib is more selective, it may still increase the risk of atrial fibrillation (arrhythmia) and bleeding. Patients should immediately report symptoms such as palpitations, dizziness, or unusual bruising to their physician. It is also critical to discuss the use of any blood thinners (anticoagulants) with a healthcare provider.

No, grapefruit and grapefruit juice can significantly increase acalabrutinib levels in the body by inhibiting the liver enzymes responsible for its metabolism. This may lead to increased toxicity and more severe side effects. It is recommended to completely avoid grapefruit products while on this medication.